Compagnie Lombard Odier SCmA’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-850	Closed	-$51K	–	596
2018 Q3	$51K	Buy	+850	New	+$49.6K	﹤0.01%	423
2015 Q1	–	Sell	-24,800	Closed	-$1.25M	–	967
2014 Q4	$1.25M	Hold	24,800	–	–	0.06%	159
2014 Q3	$1.15M	Hold	24,800	–	–	0.05%	170
2014 Q2	$1.08M	Buy	+24,800	New	+$1M	0.04%	182

Other funds holding PBE

ACM

Arlington Capital Management Arlington Heights, Illinois $177M AUM 44.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Compagnie Lombard Odier SCmA's PBE Position: Q4 2018 in Review

Compagnie Lombard Odier SCmA sold out of Invesco Biotechnology & Genome ETF (PBE) in Q4 2018, closing a stake of 850 shares — an estimated $51K sold.

Compagnie Lombard Odier SCmA first reported a position in PBE in Q2 2014 and held it in 4 quarters. The position peaked at $1.25M in Q4 2014. 71 funds tracked by Wall St. Rank hold PBE as of Q4 2018.

Compagnie Lombard Odier SCmA reported no remaining Invesco Biotechnology & Genome ETF position as of Q4 2018 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 850 Invesco Biotechnology & Genome ETF shares in Q4 2018, an estimated $51K.
Compagnie Lombard Odier SCmA first reported a position in Invesco Biotechnology & Genome ETF in Q2 2014 and held it in 4 quarters.
Compagnie Lombard Odier SCmA's Invesco Biotechnology & Genome ETF position peaked at $1.25M in Q4 2014.
71 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q4 2018.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q4 2018, filed 13 Feb 2019.